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Processing of O6-methylguanine by mismatch correction in
human cell extracts
Sabrina Ceccotti*, Gabriele Aquilina*, Peter Macpherson†, Masami Yamada†,
Peter Karran† and Margherita Bignami*
Human cell extracts perform an aberrant form of DNA
synthesis on methylated plasmids [1], which represents
processing of O6-methylguanine (O6-meG). Here, we
show that extracts of colorectal carcinoma cells with
defects in the mismatch repair proteins that normally
correct replication errors do not carry out this synthesis.
hMSH2-defective LoVo cell extracts (hMSH for human
MutS homologue) performed O6-meG-dependent DNA
synthesis only after the addition of the purified hMutSa
mismatch recognition complex. Processing of O6-meG
by mismatch correction requires PCNA and therefore
probably DNA polymerase d and/or e. Mismatch 
repair-defective cells withstand O6-meG in their DNA
[2], making them tolerant to methylating agents.
Methylation-tolerant HeLaMR clones, with a mutator
phenotype and a defect in either mismatch recognition
or correction in vitro, also performed little O6-meG-
dependent DNA synthesis. Assays of pairwise
combinations of tolerant and colorectal carcinoma cell
extracts identified hMLH1 as the missing mismatch
repair function in a group of tolerant clones. The
absence of processing by extracts of methylation-
tolerant cells provides the first biochemical evidence
that lethality of DNA O6-meG derives from its
interaction with mismatch repair.
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Results and discussion
HeLa cell extracts perform non-replicative DNA synthesis
on plasmids methylated with N-methyl-N-nitrosourea
(MNU) and containing approximately one O6-meG per
molecule [1]. Three lines of evidence indicate that this
DNA synthesis represents processing of O6-meG. First,
pretreatment of MNU-treated plasmid with a purified
recombinant human O6-meG–DNA methyltransferase
(MGMT), which selectively removes the methyl group
from O6-meG in DNA, reduces the extent of this type of
DNA synthesis (Fig. 1a and [1]). Second, active MGMT in
extracts of Mex+ HeLaS3 cells (Mex+ denotes expression
of MGMT) decreases the level of DNA synthesis to
approximately half that carried out by Mex– HeLaMR
extracts, which do not contain detectable MGMT (Fig. 1a
and [3]). And third, the aberrant DNA synthesis does not
occur to a significant extent on a methyl methanesulfonate-
treated substrate that contains essentially no O6-meG [1].
To determine whether mismatch correction was involved in
processing DNA O6-meG, we assayed extracts of the col-
orectal carcinoma cell lines LoVo (hMSH2–) [4], HCT116
(hMLH1–) [5] and DLD-1 (hMSH6/GTBP–) [6], which have
defined defects in mismatch repair proteins (reviewed in
[7]), for their ability to incorporate labelled dAMP into the
MNU-treated substrate. They all carried out significantly
less O6-meG-dependent DNA synthesis than HeLaS3 cell
extracts (Fig. 1a), although they contained comparable
levels of MGMT ([8] and data not shown). These results
suggest that mismatch repair is required to process persis-
tent DNA O6-meG. Extracts from SW48 cells, which are
defective in hMLH1 [9] and are Mex– [8], incorporated little
labelled dAMP into the methylated substrate compared
with mismatch-repair-proficient Mex– SW620 cell extracts
(Fig. 1b). Our observations with Mex+ and Mex– cell
extracts therefore indicate that aberrant synthesis at
O6-meG is carried out by the mismatch correction pathway.
Addition of hMutSa, extensively purified by selective
ATP elution from single-stranded DNA cellulose [10], to
extracts of LoVo (hMSH2–) cells restored their ability to
perform O6-meG-dependent DNA synthesis. Unsupple-
mented LoVo cell extracts incorporated less than 0.1 pmole
dAMP in the assay; in the presence of ~10 fmole hMutSa,
the extent of incorporation was similar to that carried out
by extracts of mismatch-repair-proficient Raji or HeLaS3
cells (Fig. 1c and data not shown). In contrast, incorpora-
tion by SW48 (hMLH1–) cell extracts was unaffected by
hMutSa. Thus, when the missing hMSH2, in the form of
the hMutSa heterodimer, is supplied to LoVo cell extracts,
they acquire the ability to process O6-meG. As hMutSa
was identified by complementing the mismatch repair
defect in LoVo cell extracts [10], these data provide direct
confirmation that  the aberrant DNA synthesis at O6-meG
is carried out by mismatch correction. The inability of
hMutSa to complement the mismatch correction defect in
SW48, is consistent with this interpretation.
Biochemical fractionation studies previously suggested that
O6-meG-dependent DNA synthesis requires DNA poly-
merase d or e [1]. To investigate this further, we measured
DNA synthesis in the presence of immunoglobulin G (IgG)
purified from a polyclonal rabbit anti-human PCNA anti-
serum. Preincubation of HeLaMR extracts with increasing
concentrations of the antibody progressively inhibited O6-
meG-dependent DNA synthesis by up to 80 % (Fig. 1d).
The dependence of O6-meG-induced DNA synthesis on
PCNA indicates that hMSH2–hMLH1-dependent mis-
match repair requires DNA polymerase d or e.
Resistance to methylating drugs can arise by loss of DNA
mismatch repair, and mismatch-repair-defective cells tol-
erate O6-meG in their DNA [2]. Several independent,
methylation-tolerant variants of HeLaMR cells were iso-
lated by repeated exposure to MNNG [11]. Clones 6, 7, 12
and 41 have increased spontaneous mutation rates at
microsatellite repeats (>15-fold) and at the hypoxanthine
guanine phosphoribosyltransferase locus (4–15-fold; [11]
and C. Ciotta, G.A., S.C. and M.B., data not shown). We
performed band-shift assays with an oligonucleotide con-
taining a single unpaired guanine to determine if any of
the clones were defective in mismatch recognition. Clone
12 extracts did not detectably recognize this substrate
(Fig. 2a) or a substrate containing a single G⋅T mispair
(data not shown), and resembled the mismatch-binding-
defective RajiF12 [12] in this regard. Clones 6, 7 and 41
could bind to both mismatched substrates and resembled
Raji (Fig. 2a) and the parental HeLaMR cells (data not
shown). Mismatch repair was investigated directly in
clones 6, 7 and 41 by measuring the ability of extracts to
repair a single G⋅T mispair in a circular heteroduplex sub-
strate [13]. Parental HeLaMR extracts corrected the G⋅T
mismatch, as judged by the creation of a ClaI-sensitive
site in a portion of the products recovered after incuba-
tion. We did not detect correction of the mismatch by
extracts of clones 6, 7 and 41 (Fig. 2b). Thus, despite their
apparently normal mismatch recognition abilities, clones
6, 7 and 41 are all defective in mismatch repair. This
suggests that they might be deficient in a later step of the
correction pathway.
Extracts of all the methylation-tolerant clones performed
little O6-meG-induced DNA synthesis, and in this
respect they were indistinguishable from the mismatch
correction-defective colorectal carcinoma cell extracts
(Fig. 3a). The mismatch repair defects in the methyla-
tion-tolerant cells are associated with a deficiency in O6-
meG-induced DNA synthesis. Analysis of the ‘repair’
products on agarose gels indicated that, whereas the low-
level background radioactivity incorporated by the
methylation-tolerant extracts was predominantly (> 70 %)
in ligated molecules, ≤ 30 % of the incorporation by the
HeLaMR extracts was associated with ligated DNA (Fig.
3b). The low background incorporation by the tolerant
cell extracts probably represents completed excision
repair of methylated bases other than O6-meG [3]. Thus,
there are both qualitative and quantitative differences in
O6-meG processing by wild-type and tolerant cell
extracts. O6-meG-induced DNA synthesis is not only
more extensive in wild-type compared with tolerant cell
extracts, but is also associated with DNA repair events
that remain incomplete.
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Figure 1
O6-meG-dependent DNA synthesis on MNU-
treated plasmid pKSoriSV. (a) The incorporation
of dAMP by various amounts of extracts from
Mex– HeLaMR cells and Mex+ HeLaS3, LoVo,
DLD1 and HCT116 cells was determined
following incubation with methylated plasmid for
30 min at 37 °C. The broken line indicates
incorporation into a methylated plasmid
pretreated with 0.5 units of MGMT for 15 min
before addition to the HeLaMR extract. (b)
Incorporation of dAMP by extracts of the Mex–
colorectal carcinoma cells SW620 and SW48
(consistent with their slower growth rate,
SW620 cell extracts incorporated less dAMP
than HeLaMR extracts). (c) dAMP incorporation
by extracts of Raji cells, or of LoVo and SW48
cells in the presence or absence of 10 fmole
partially purified hMutSa. (d) Extracts from
HeLaMR cells were preincubated for 15 min at
room temperature in the presence or absence of
the indicated concentrations of anti-PCNA IgG,
before addition of the methylated DNA substrate
and labelled precursors. In (a–d), incorporation
of radioactive dAMP into DE81-adsorbed
material was determined as described in [1].
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Restoration of O6-meG-induced DNA synthesis by in
vitro complementation was used to diagnose the molecu-
lar defects in mismatch correction in the tolerant clones.
When extracts of clones 6, 7 or 41 were combined pair-
wise, there was no detectable increase in O6-meG-depen-
dent DNA synthesis, suggesting that they might share a
common defect. The ability to perform this DNA synthe-
sis was restored to extracts of clone 6, 7 and 41 by adding
extracts from DLD-1 (hMSH6/GTBP–) cells. Complemen-
tation was essentially complete and the extent of dAMP
incorporation by the combined extracts was comparable to
that of HeLaS3 extracts. In contrast, no complementation
was observed when extracts of the tolerant clones were
combined with extracts of HCT116 (hMLH1–) cells.
HCT116 cell extracts were, however, able to comple-
ment the defect in O6-meG-dependent synthesis in
DLD-1 extracts (Fig. 3c). Clones 6, 7 and 41 therefore
belong to the same complementation group for O6-meG-
dependent synthesis as the colorectal cell line HCT116,
indicating that the mismatch-repair defect in these clones
is in hMLH1.
The occurrence of O6-meG-related DNA synthesis indi-
cates that the methylated base can be processed by
extracts of human cells [1,3]. The use of colorectal carci-
noma cell lines with known defects in mismatch repair
now provides direct evidence that O6-meG processing
occurs by mismatch correction. This processing requires
Figure 2
Mismatch correction activities in tolerant cell
extracts. (a) Mismatch binding activity in
extracts from Raji cells, its methylation-tolerant
derivative Raji F12, and the tolerant HeLaMR
derivatives, clones 6, 7, 41 and 12, was
determined by band-shift analysis using the
heteroduplex substrate shown above. S,
mismatch-specific complex; N, non-specific
complex. (b) Correction of a single G⋅T mispair
by tolerant cell extracts. Cell extracts were
incubated with circular M13 heteroduplex
molecules containing a single G⋅T mismatch
and a nick (the numbers in brackets indicate
distance from the mismatch in kbp). Recovered
DNA was linearized with AlwNI, digested with
ClaI (which selectively cuts repaired DNA
molecules into two diagnostic  fragments of 3.2
and 4.2 kbp) and analyzed by agarose gel
electrophoresis and Southern blotting.
Clal
Nick (7.0)
HK7
7.4 kb
AlwNI (3.2)
ATCGATGCTGGTGGAGTGTGTGACGGT GTGGAGCTGACCTCACTTAA
ACCACCTCACACACTGCCA CACCTCGACTGGAGTGAATT TAGCTGCG
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Figure 3
O6-meG-dependent DNA synthesis on MNU-
treated pKSoriSV by extracts of tolerant human
cells. (a) Extracts from HeLaMR and clones 12,
6, 7 and 41 were incubated with the methylated
plasmid and the level of incorporation of
radioactive dAMP was determined. (b) MNU-
treated (+) or untreated plasmid (–) was
incubated with 100 mg extract from HeLaMR, or
clones 7, 6 or 41. The radioactive DNA products
were separated by agarose gel electrophoresis
and detected by autoradiography. The positions
of ligated (RFI) and nicked (RFII) plasmids are
shown. (c) O6-meG-dependent DNA synthesis
was measured in extracts (100 mg) of the
methylation-tolerant clones 6, 7 and 41 and the
colorectal carcinoma cell lines HCT116 and
DLD-1, either alone or in the pairwise
combinations shown (100 mg each). Mex–
HeLaMR and Mex+ HeLaS3 extracts (100 mg)
were used as controls. In (a,c), incorporation of
radioactive dAMP into DE81-adsorbed material
was determined as described in [1].
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PCNA, indicating that the hMSH2–hMLH1 mismatch
repair pathway involves DNA polymerase d and/or e.
O6-meG apparently requires the intervention of mismatch
repair to convert it into a lethal lesion, and tolerance to
DNA methylation damage arises by loss of mismatch repair
[12,14–16]. The mechanism by which mismatch correction
promotes O6-meG lethality has remained undefined. The
reduced level of O6-meG-related DNA synthesis by
extracts of both mismatch-repair-defective and methyla-
tion-tolerant cell lines suggests that the DNA synthesis
reflects lethal processing of the methylated base. Consider-
able evidence indicates that, despite their resistance to its
lethal effects, O6-meG remains in the DNA of tolerant cells
[17]. This has led to the proposal that mismatch repair is
engaged non-productively, that it is incorrectly targeted to
the complementary strand and so does not remove O6-meG
from DNA [2]. This is consistent with our observation of
O6-meG-dependent synthesis by extracts of normal, but
not mismatch-repair-defective tolerant, cells. It is also in
agreement with the finding that most of the O6-meG-
dependent synthesis by normal cell extracts is associated
with incompletely repaired plasmids.
The mismatch repair deficiencies in methylation-tolerant
cells are the same as those found in both familial and
sporadic colorectal cancers. Selection for the methylation-
tolerant phenotype provides a ready source of repair-
defective cell lines, and the use of the O6-meG-processing
assay provides a new approach to elucidate the steps of
human mismatch repair.
Materials and methods
Cell lines and culture
HeLaS3, HeLaMR and tolerant variants were grown in DMEM (GIBCO)
containing 10 % fetal bovine serum (FBS); Raji and RajiF12 cells were
grown in RPMI containing 10 % FBS. Colorectal carcinoma cells (from C.
Dixon) were grown in a-MEM containing 15 % calf serum.
Preparation of the substrate
Plasmid pKSoriSV, which contains the HindIII–SalI fragment of pSVori,
including the SV40 origin of replication, in pBluescript, was methylated with
0.48 mM MNU for 30 min at 37 °C in TE (pH 7.5). Methylated bases were
quantitated as previously described [1].
Cell extracts, in vitro O6-meG-dependent synthesis and anti-
human PCNA antibodies
Cell extracts were prepared and assays were carried out as described [1].
O6-meG-dependent synthesis was calculated by subtracting incorporation
into the unmodified plasmid (typically around 20 % of the MNU-treated
value) from that into the MNU-treated substrate. An IgG fraction from a poly-
clonal rabbit anti-human PCNA antiserum was obtained from D.P. Lane.
Partial purification of hMutSa mismatch binding complex
hMutSa was purified from Raji cells essentially as described [10], omitting
the final MonoQ step. The preparation contained two prominent Coomassie
Blue-staining bands of 100 and 160 kDa which comprised >50 % of the
proteins present.
Binding assay
Preparation of cell extracts and binding to mismatched duplexes was
carried out as described [12]. The labeled substrate was either a 39mer
containing a single unpaired guanine or a 34mer containing a single G.T
mismatch [12].
Heteroduplex construction and in vitro mismatch repair
Bacteriophage M13 constructs (HK7) were obtained from P. Brooks.
Duplex circular molecules containing a nick and a G.T mispair were pre-
pared essentially as described [13]. Assays (20 ml) containing 70 mg cell
extract were carried out as described in [18]. Purified DNA was linearized
with AlwNI and incubated with ClaI. Digested products were separated on
1 % agarose and visualized by autoradiography following Southern transfer.
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